Evidence map›Paper›PMID 41009364›Full record

ReviewInternational journal of molecular sciences2025

Monoclonal Antibodies: Historical Perspective and Current Trends in Biological Drug Development.

Barbara Madej, Filip Tomaszewski, Dagmara Szmajda-Krygier, Rafał Świechowski, Agnieszka Jeleń, Marek Mirowski

Abstract readReviewHistorical Article
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Barbara MadejLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Filip TomaszewskiLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Dagmara Szmajda-KrygierLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-9524-6032
Rafał ŚwiechowskiLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-2923-273X
Agnieszka JeleńLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-3565-7075
Marek MirowskiLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-9243-0275

Funding

Medical University of Lodz No. 503/3-015-02/503-31-001
6 · The paper itself

Abstract

Antibodies, also called immunoglobulins, play a key role in the body's immune response, binding to specific molecular targets. Of the five classes of antibodies, IgG has found the greatest clinical application. The article presents the mechanisms of antibody action, including interactions with FcR receptors on leukocytes, complement activation, and direct cytotoxic interactions, as well as the main methods of antibody production, which include hybridoma technology, phage display, and production using transgenic animals and their modifications, which allowed for the production of antibodies with reduced immunogenicity and increased their effectiveness and safety of use. It also characterizes various types of antibodies and presents the differences between them resulting from the structure and content of individual protein domains encoded by human genes and genes from other species. Antibodies are currently one of the most important groups of biological drugs used in the treatment of autoimmune, infectious, and neoplastic diseases. The properties of these large biomolecules and the achievements in the field of obtaining and modifying antibodies mean that they are currently the subject of many studies. New forms of antibodies, such as antibody-drug conjugates with highly potent cytotoxic agents, bispecific antibodies, and nanobodies, demonstrate an innovative approach to the treatment of cancer and autoimmune diseases. The dynamic development of the antibody market indicates its growing importance in modern pharmacy and medicine. Further research in this area may lead to the development of more effective and precise therapies, as well as to increase the safety of their use.

Indexed as

Antibodies, MonoclonalDrug DevelopmentAnimalsAntibodies, BispecificHistory, 20th CenturyHistory, 21st CenturyHumansNeoplasmsAntibodies, BispecificAntibodies, Monoclonalantibodyantibody drug conjugates (ADCs)bispecific antibodyhybridoma technologymechanisms of actionnanobodyphage displaytransgenic animals

Identifiers

PMID41009364
PMCPMC12469596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.